Epix Pharmaceuticals   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Lexington MA United States (1988)
Status: Defunct (2009)

Organization Overview

First Clinical Trial
2005
NCT00248183
First Marketed Drug
2008
gadofosveset trisodium (ablavar)
First NDA Approval
2008
gadofosveset trisodium (ablavar)
Last Known Activity
2008

Timeline

NOW
  • Now

Alternative names

Epix Pharmaceuticals, Inc.

Active Ingredients

Marketed Drugs (1)

gadofosveset trisodium (ablavar) (2008 NDA)

Drugs in Phase 3 Trials (1)

naluzotan (2 trials)

Drugs in Phase 2 Trials (3)

donepezil (aricept) (1 trial)

prx-03140 (3 trials)

prx08066 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Anxiety Disorders (Phase 3)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Disease (Phase 2)

Hypertension (Phase 2)

Hypertension, Pulmonary (Phase 2)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 4